WT1 peptide-based immunotherapy for patients with lung cancer: Report of two cases
WT1 peptide-based immunotherapy for patients with lung cancer: Report of two cases
复制标题
DOI：
10.1111/j.1348-0421.2004.tb03503.x
复制
发表时间：
2004-01-01
影响因子：
2.6
通讯作者：
Sugiyama, H
中科院分区：
文献类型：
--
作者：
Tsuboi, A;Oka, Y;Sugiyama, H
Wilms肿瘤基因WT1在各种类型的实体肿瘤中过表达，包括肺癌和乳腺癌，WT1蛋白是这些恶性肿瘤的肿瘤抗原。在基于WT1肽的癌症免疫治疗的I期临床试验中，两名晚期肺癌患者皮内注射了0.3 mg受HLA-A*2402限制的9聚WT1肽，该肽与Montanide ISA51佐剂乳化。每隔2周连续接种WT1疫苗可减少肿瘤标志物，如绒毛膜胚胎抗原（CEA）和唾液Lewis (x) (SLX)，并使肿瘤大小短暂缩小。除WT1疫苗注射部位出现局部红斑外，未见其他不良反应。这些结果为我们提供了第一个临床证据，证明基于WT1肽的免疫疗法应该是一种有希望的肺癌治疗方法。
The Wilms' tumor gene WT1 is overexpressed in various types of solid tumors, including lung and breast cancer and WT1 protein is a tumor antigen for these malignancies. In phase I clinical trials of WT1 peptide-based cancer immunotherapy, two patients with advanced lung cancer were intradermally injected with 0.3 mg of an HLA-A*2402-restricted, 9-mer WT1 peptide emulsified with Montanide ISA51 adjuvant. Consecutive WT1 vaccination at 2-week intervals resulted in a reduction in tumor markers such as chorio-embryonic antigen (CEA) and sialyl Lewis (x) (SLX) and by a transient decrease in tumor size. No adverse effects except for local erythema at the injection sites of WT1 vaccine were observed. These results provided us with the first clinical evidence demonstrating that WT1 peptide-based immunotherapy should be a promising treatment for patients with lung cancer.